CELYAD ONCOLOGY SA Inactive Instrument
Celyad Oncology SA Share Price OTC Markets
Equities
CYADY
US1512052002
Biotechnology & Medical Research
| Sales 2022 | - | Sales 2023 | 102K 110K 9.16M | Capitalization | 16.16M 17.39M 1.45B |
|---|---|---|---|---|---|
| Net income 2022 | -40M -43.05M -3.59B | Net income 2023 | -8M -8.61M -718M | EV / Sales 2022 | - |
| Net cash position 2022 | 12.19M 13.12M 1.09B | Net cash position 2023 | 5.95M 6.4M 534M | EV / Sales 2023 | 100 x |
| P/E ratio 2022 |
-0.28
x | P/E ratio 2023 |
-1.19
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celyad Oncology SA
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 24/07/24 |
David Georges
DFI | Director of Finance/CFO | - | 01/19/01 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 24/07/24 |
Hilde Windels
CHM | Chairman | 59 | 07/18/07 |
Serge Goblet
BRD | Director/Board Member | - | 01/08/01 |
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
20/09/2024
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +19.41% | 45.51B | |
| -8.62% | 38.52B | |
| +38.65% | 38.13B | |
| +26.95% | 30.74B | |
| -13.50% | 26.03B | |
| +10.74% | 25.92B | |
| +44.87% | 14.13B | |
| +34.36% | 12.73B | |
| -7.14% | 11.29B |
